Skip to main content
Premium Trial:

Request an Annual Quote

Silence Consolidates Operations Following Intradigm Acquisition

Premium

Silence Therapeutics said this week that it has begun a consolidation effort to streamline its operations following its acquisition of Intradigm (RNAi News 12/17/2009).

According to Silence, all research activities of the merged company will be conducted at its Berlin location. Silence, which is based in London, has maintained German operations since its 2005 acquisition of Atugen (RNAi News 7/29/2005).

Other functions including operations, business development, legal, and "certain drug-development activities, will be conducted in Palo Alto," Calif., where Intradigm was headquartered.

Silence said that as a result of the consolidation, it has laid off about 20 staffers, primarily in research and development, at both the Palo Alto and Berlin sites. The reorganization is expected to be completed in June.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.